| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Vivekananda Rachamallu, Ayman Haq, Michael M Song, Manish Aliget. Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. Case reports in psychiatry. vol 2017. 2020-09-30. PMID:28835863. |
here, we report on the development of clozapine-induced microseizures, orofacial dyskinesia, and stuttering in a 17-year-old adolescent male with treatment of refractory early onset schizophrenia on clozapine and concurrent lithium therapy. |
2020-09-30 |
2023-08-13 |
Not clear |
| Vivekananda Rachamallu, Ayman Haq, Michael M Song, Manish Aliget. Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. Case reports in psychiatry. vol 2017. 2020-09-30. PMID:28835863. |
the patient's symptoms of schizophrenia responded well to the clozapine regimen. |
2020-09-30 |
2023-08-13 |
Not clear |
| Basel A Abdel-Wahab, Metwally E Metwall. Clozapine-induced cardiotoxicity in rats: Involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicology reports. vol 1. 2020-09-30. PMID:28962331. |
clozapine, an ideal antipsychotic drug for the treatment of resistant schizophrenia, is considered the most underutilised treatment for schizophrenia. |
2020-09-30 |
2023-08-13 |
rat |
| Thomas E Winkler, Florence O Stevenson, Eunkyoung Kim, Mijeong Kang, Gregory F Payne, Deanna L Kelly, Reza Ghodss. The Role of Microsystems Integration Towards Point-of-Care Clozapine Treatment Monitoring in Schizophrenia. IEEE sensors letters. vol 2. issue 1. 2020-09-30. PMID:29308452. |
the role of microsystems integration towards point-of-care clozapine treatment monitoring in schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Thomas E Winkler, Florence O Stevenson, Eunkyoung Kim, Mijeong Kang, Gregory F Payne, Deanna L Kelly, Reza Ghodss. The Role of Microsystems Integration Towards Point-of-Care Clozapine Treatment Monitoring in Schizophrenia. IEEE sensors letters. vol 2. issue 1. 2020-09-30. PMID:29308452. |
our study is specifically geared toward schizophrenia treatment, where concurrent blood monitoring of the antipsychotic clozapine and white blood cells could lead to improved treatment outcomes. |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrew Shaker, Rowena Jone. Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. Therapeutic advances in psychopharmacology. vol 8. issue 1. 2020-09-30. PMID:29344339. |
clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrew Shaker, Rowena Jone. Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. Therapeutic advances in psychopharmacology. vol 8. issue 1. 2020-09-30. PMID:29344339. |
research in patients with treatment-resistant schizophrenia has demonstrated that clozapine discontinuation is associated with poor outcomes. |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrew Shaker, Rowena Jone. Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. Therapeutic advances in psychopharmacology. vol 8. issue 1. 2020-09-30. PMID:29344339. |
there is, however, a paucity of research investigating the impact of clozapine discontinuation specifically in younger patients with more recent onset schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Andrew Shaker, Rowena Jone. Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service. Therapeutic advances in psychopharmacology. vol 8. issue 1. 2020-09-30. PMID:29344339. |
a case note review was therefore conducted to ascertain medium-term prognoses in patients with treatment-resistant schizophrenia under an early intervention service (eis) following clozapine discontinuation. |
2020-09-30 |
2023-08-13 |
Not clear |
| Afaque H Khan, Samina Zaid. Clozapine: Improvement of Negative Symptoms of Schizophrenia. Cureus. vol 9. issue 12. 2020-09-30. PMID:29492362. |
clozapine: improvement of negative symptoms of schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Afaque H Khan, Samina Zaid. Clozapine: Improvement of Negative Symptoms of Schizophrenia. Cureus. vol 9. issue 12. 2020-09-30. PMID:29492362. |
clozapine has been established to be more beneficial than conventional antipsychotics in patients with treatment-resistant schizophrenia and apparently more useful, based on existing evidence, in managing the negative symptoms of schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Marta Szlachta, Maciej Kuśmider, Paulina Pabian, Joanna Solich, Magdalena Kolasa, Dariusz Żurawek, Marta Dziedzicka-Wasylewska, Agata Faron-Góreck. Repeated Clozapine Increases the Level of Serotonin 5-HT Frontiers in molecular neuroscience. vol 11. 2020-09-30. PMID:29497362. |
repeated clozapine increases the level of serotonin 5-ht g-protein-coupled receptor (gpcr) heterodimers are new targets for the treatment of schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, Domenico Di Nicola, Carmine Tomasetti, Alessandro Valchera, Michele Fornaro, Fabio Di Fabio, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Federica Vellante, Laura Orsolini, Giovanni Martinotti, Massimo Di Giannantoni. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic advances in drug safety. vol 9. issue 5. 2020-09-30. PMID:29796248. |
safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. |
2020-09-30 |
2023-08-13 |
Not clear |
| Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, Domenico Di Nicola, Carmine Tomasetti, Alessandro Valchera, Michele Fornaro, Fabio Di Fabio, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Federica Vellante, Laura Orsolini, Giovanni Martinotti, Massimo Di Giannantoni. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic advances in drug safety. vol 9. issue 5. 2020-09-30. PMID:29796248. |
clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical antipsychotic approved for the treatment of resistant schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, Domenico Di Nicola, Carmine Tomasetti, Alessandro Valchera, Michele Fornaro, Fabio Di Fabio, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Federica Vellante, Laura Orsolini, Giovanni Martinotti, Massimo Di Giannantoni. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic advances in drug safety. vol 9. issue 5. 2020-09-30. PMID:29796248. |
as poor treatment adherence in patients with resistant schizophrenia may increase the risk of a psychotic relapse, which may further lead to impaired social and cognitive functioning, psychiatric hospitalizations and increased treatment costs, clozapine adverse effects are a common reason for discontinuing this medication. |
2020-09-30 |
2023-08-13 |
Not clear |
| Jung Hyun Kim, Tak Youn, Jun Gwon Choi, Seong Hoon Jeong, Hee Yeon Jung, Yong Sik Kim, In Won Chun. Combination of Electroconvulsive Therapy and Clozapine in Treatment-Resistant Schizophrenia. Psychiatry investigation. vol 15. issue 8. 2020-09-30. PMID:30086612. |
combination of electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |
| Allison Karst, Jonathan Liste. Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: A case report and discussion. The mental health clinician. vol 8. issue 5. 2020-09-30. PMID:30206510. |
clozapine remains the definitive gold standard for treatment-resistant schizophrenia despite limitations in use because of hematological abnormalities. |
2020-09-30 |
2023-08-13 |
Not clear |
| Alex Till, James Selwood, Edward Silv. The assertive approach to clozapine: nasogastric administration. BJPsych bulletin. vol 43. issue 1. 2020-09-30. PMID:30223913. |
results: five of the most extremely ill patients with treatment-resistant schizophrenia were established and/or maintained on clozapine, resulting in improvements to their mental state; incidents were reduced, segregation was terminated and progression to less restrictive environments was achieved.clinical implicationsdespite being underutilised and rarely enforced, in extreme circumstances, an assertive approach to clozapine can be justified. |
2020-09-30 |
2023-08-13 |
Not clear |
| Alex Till, James Selwood, Edward Silv. The assertive approach to clozapine: nasogastric administration. BJPsych bulletin. vol 43. issue 1. 2020-09-30. PMID:30223913. |
nasogastric clozapine can be safely delivered and the approach itself, rather than actual nasogastric administration, may be enough to help establish and maintain patients with treatment-resistant schizophrenia on the most effective treatment.declaration of intereste.s. |
2020-09-30 |
2023-08-13 |
Not clear |
| Bryan K Sackey, Troy A Moore, Nicole L Cupples, Cynthia A Gutierre. Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition. The mental health clinician. vol 8. issue 6. 2020-09-30. PMID:30397572. |
the second patient was a 45-year-old black male who was initiated on clozapine for treatment-resistant schizophrenia. |
2020-09-30 |
2023-08-13 |
Not clear |